Evaluation of Changes in Tumor Shadows and Microcalcifications on Mammography Following KORTUC II, a New Radiosensitization Treatment without any Surgical Procedure for Elderly Patients with Stage I and II Breast Cancer.
Evaluation of Changes in Tumor Shadows and Microcalcifications on Mammography Following KORTUC II, a New Radiosensitization Treatment without any Surgical Procedure for Elderly Patients with Stage I and II Breast Cancer.
复制标题
DOI：
10.3390/cancers3033496
复制
发表时间：
2011-09-09
期刊：
影响因子：
5.2
通讯作者：
Miyamura M
中科院分区：
文献类型：
--
作者：
Tsuzuki A;Ogawa Y;Kubota K;Tokuhiro S;Akima R;Yaogawa S;Itoh K;Yamada Y;Sasaki T;Onogawa M;Yamanishi T;Kariya S;Nogami M;Nishioka A;Miyamura M
我们在早期乳腺癌治疗中引入了一种新型酶靶向放射增敏治疗的非手术疗法，即Kochi Oxydol-放射治疗不可切除的癌症II型（KORTUC II）。本研究的目的是检查老年乳腺癌患者接受KORTUC II后乳房X光检查（MMG）上肿瘤阴影和微钙化的变化。我们还试图确定MMG是否可用于评价KORTUC II的治疗效果。除MMG外，还进行了正电子发射断层扫描-计算机断层扫描（PET-CT）以检测转移和局部复发。在所有10名患者中，MMG上的肿瘤阴影在KORTUC II治疗后几个月内完全消失。伴随的微钙化也消失或数量明显减少。KORTUC II治疗后MMG上的肿瘤密度曲线也证实了肿瘤消失;密度下降，最终接近外周乳腺组织的密度。到目前为止，这10例患者在PET-CT上也没有显示局部复发或远处转移，平均随访期约为27个月，截至2010年9月底。我们的结论是，保乳治疗使用KORTUC II，其次是芳香化酶抑制剂，是一个有前途的治疗方法，为老年乳腺癌患者，在避免任何手术。此外，认为MMG可用于评价KORTUC II的疗效。
We introduced non-surgical therapy with a novel enzyme-targeting radiosensitization treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II) into early stages breast cancer treatment. The purpose of this study was to examine changes in tumor shadows and microcalcifications on mammography (MMG) following KORTUC II for elderly patients with breast cancer. We also sought to determine whether MMG was useful in evaluating the therapeutic effect of KORTUC II. In addition to MMG, positron emission tomography-computed tomography (PET-CT) was performed to detect both metastasis and local recurrence. In all 10 patients, tumor shadows on MMG completely disappeared in several months following the KORTUC II treatment. The concomitant microcalcifications also disappeared or markedly decreased in number. Disappearance of the tumors was also confirmed by the profile curve of tumor density on MMG following KORTUC II treatment; density fell and eventually approached that of the peripheral mammary tissue. These 10 patients have so far have also shown neither local recurrence nor distant metastasis on PET-CT with a mean follow-up period of approximately 27 months at the end of September, 2010. We conclude that breast-conservation treatment using KORTUC II, followed by aromatase inhibitor, is a promising therapeutic method for elderly patients with breast cancer, in terms of avoiding any surgical procedure. Moreover, MMG is considered to be useful for evaluating the efficacy of KORTUC II.